# Ucello Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ucello-therapeutics

- Industry: Biotechnology
- Headquarters: Chengdu, China
- Website: www.ucello.cn
- Total disclosed funding: $46M
- Latest round: Series A (Jun 2, 2023)
- Investors on record: 9

## About

Based in Chengdu, China and founded in 2020, Ucello Therapeutics operates as a biotechnology company engaged in the R & D and production of universal CAR-T cell therapeutic drugs. In June 2023, Ucello Therapeutics raised CNY 150 million in series A+ funding led by new investor Juke Investment. Other new investors Penglai Capital, Chengdu Biocity Equity Investment Fund Management, Shenzhen Guozhong Venture Capital and returning investors Matrix Partners China, and Co-Win Ventures also participated in the round. The round was part of a larger CNY 310 million series A funding.


The company's core technologies include cell culture technique, gene editing and plasmid virus. Based on its universal CAR-T cell technology platform CBT-X20, the company has developed several cell therapy products for malignant tumors.

## Funding rounds

- Series A, Jun 2, 2023, $21M — Co-Win Ventures, MPC, Shenzhen Guozhong Venture Capital, BIO-TOWN Capital, Juke Investment, Penglai Capital
- Series A, Feb 10, 2022, $25M — NLVC, Co-Win Ventures, MPC, Chengdu Tianfu International Bio-Town Investment & Development Co., Ltd., Elikon Venture

## Investors

- NLVC (https://capitalatlas.ai/funds/nlvc) — Series A
- Co-Win Ventures (https://capitalatlas.ai/funds/co-win-ventures) — Series A
- MPC — Series A
- Chengdu Tianfu International Bio-Town Investment & Development Co., Ltd. — Series A
- Elikon Venture (https://capitalatlas.ai/funds/elikon-venture) — Series A
- Shenzhen Guozhong Venture Capital (https://capitalatlas.ai/funds/shenzhen-guozhong-venture-capital) — Series A
- BIO-TOWN Capital (https://capitalatlas.ai/funds/bio-town-capital) — Series A
- Juke Investment — Series A
- Penglai Capital — Series A